View Older Stories View More Recent Stories

Jan 15, 2026 02:07PM Sun Pharma Announces the Availability of UNLOXCYT™ (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)
Nov 25, 2025 10:51PM FDA approves label update for Sun Pharma's UNLOXCYT cancer drug
Nov 25, 2025 10:51PM FDA approves label update for UNLOXCYT™ (cosibelimab-ipdl) based on longer-term data that demonstrated improved clinical outcomes in advanced cutaneous squamous cell carcinoma (aCSCC)
Oct 22, 2025 11:00AM Sun Pharma Announces Jeremy Allen as Vice President, Corporate Affairs for North America
May 30, 2025 10:39AM Sun Pharma Completes its Acquisition of Checkpoint Therapeutics
May 16, 2025 08:58AM Sun Pharma Announces FDA Approval of Next Generation BLU-U® Blue Light Photodynamic Therapy Illuminator for Actinic Keratosis
Apr 24, 2025 02:28AM Sun Pharma and Moebius Medical Announce Dual Publications on MM-II's Phase 2b Clinical Trial Results and Mechanism of Action in Osteoarthritis and Cartilage
Apr 4, 2025 08:15AM Music Icon Art Garfunkel Opens Up About His Experience with Psoriasis for The First Time in Partnership with Sun Pharma
Mar 9, 2025 10:07PM Sun Pharma to Acquire Checkpoint Therapeutics
Mar 9, 2025 10:06PM Sun Pharma to Acquire Checkpoint Therapeutics
Mar 7, 2025 09:15AM ILUMYA® (tildrakizumab-asmn) Found Effective for Treatment of Moderate-to-Severe Plaque Psoriasis Affecting Nails in Study Presented at 2025 AAD Conference
Oct 25, 2024 02:21PM Sun Pharma Presents LEQSELVI™ (deuruxolitinib) Data Highlighting Clinical Efficacy & Durability for Treatment of Alopecia Areata at the 2024 Fall Clinical Dermatology Conference
Oct 25, 2024 08:30AM Studies Show Sun Pharma's WINLEVI® (clascoterone) Cream 1% Reduces Sebum Levels and is Suitable for Combination With Other Commonly Used Topical Acne Medications
Oct 25, 2024 07:00AM Sun Pharma Announces Multiple Data Presentations Highlighting its Dermatology Portfolio to be Featured at the 2024 Fall Clinical Dermatology Conference
Sep 26, 2024 08:00AM Sun Pharma Presents New Clinical Efficacy and Safety Data in Severe Dermatological Conditions at the 2024 European Academy of Dermatology and Venereology (EADV) Congress
Sep 6, 2024 02:30AM Sun Pharma and Moebius Medical Announce Fast Track Designation Granted for MM-II for the Treatment of Osteoarthritis Knee Pain
Jul 26, 2024 10:22AM U.S. FDA Approves LEQSELVI™ (deuruxolitinib), an Oral JAK Inhibitor for the Treatment of Severe Alopecia Areata
Jul 25, 2024 08:09PM U.S. FDA Approves LEQSELVI™ (deuruxolitinib), an Oral JAK Inhibitor for the Treatment of Severe Alopecia Areata
Jun 24, 2024 07:47AM Sun Pharma Completes Taro Merger
Jun 14, 2024 06:34AM Oral Presentation at EULAR 2024 of Data from Global Phase 2b Clinical Trial Demonstrates Durability of Pain Relief After a Single Injection of MM-II in Patients with Painful Knee Osteoarthritis (OA)
Oct 12, 2023 06:55AM CEQUA® (cyclosporine ophthalmic solution) 0.09% Phase 4 Data Showed Sustained Improvement in Dry Eye Disease Signs and Symptoms in Patients Switched From Restasis® (cyclosporine ophthalmic emulsion)
Jun 24, 2023 08:00AM Sun Pharma Presents Data from First-in-Human Phase 1 Studies of GL0034 at the American Diabetes Association 83rd Scientific Sessions
May 30, 2023 04:56AM Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand
Mar 6, 2023 08:39AM Sun Pharma Completes Acquisition of Concert Pharmaceuticals
Jan 19, 2023 09:39AM Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata
Mar 25, 2022 07:00AM Sun Pharma Presents Phase 3 Data for WINLEVI® (clascoterone) cream 1% for the Topical Treatment of Acne Vulgaris at the AAD Annual Meeting
Mar 24, 2022 09:08AM Sun Pharma to Present Clinical Data Abstracts for ILUMYA® (tildrakizumab-asmn) in Patients with Moderate-to-Severe Plaque Psoriasis at 2022 AAD Annual Meeting
Nov 1, 2021 07:00AM Sun Pharma Announces Availability of WINLEVI® (clascoterone) cream 1% in the U.S. for Topical Treatment of Acne Vulgaris
Aug 31, 2021 08:05AM Sun Pharma and Cassiopea announce the expiry of the HSR Act process and the successful consummation of their Winlevi® (clascoterone cream 1%) agreement
Jul 26, 2021 03:46AM Sun Pharma and Cassiopea SpA Announce Signing of License and Supply Agreements for Winlevi® (clascoterone cream 1%) in US and Canada
Feb 25, 2021 05:00AM Sun Pharma Launches Website for its Long-Term Care Portfolio in the U.S.
Oct 31, 2020 11:10AM Sun Pharma Announces 5-Year Sustained Efficacy and Safety Results for ILUMYA® (tildrakizumab-asmn) in Patients with Moderate-to-Severe Plaque Psoriasis
Jun 12, 2020 03:21PM Sun Pharma Announces Long-term Insights into the Clinical Use of ILUMYA™ (tildrakizumab-asmn) in a Cross Section of People Living with Moderate-to-Severe Plaque Psoriasis
Jun 12, 2020 03:21PM Sun Pharma Presents ODOMZO® and LEVULAN® KERASTICK® + BLU-U® Data, Offering Clinical Insights for Treating People with or at Risk of Skin Cancer
Mar 27, 2020 03:00PM Sun Pharmaceutical Industries, Inc. Donates 2.5 Million Hydroxychloroquine Sulfate Tablets in the U.S. For Potential COVID-19 Treatment
Feb 26, 2020 05:00AM Sun Pharma Launches RIOMET ER Oral Suspension in the U.S.
Feb 10, 2020 07:45AM Sun Pharma Launches New Ad Campaign to Raise Awareness of Acne and its Impact on Everyday Life
Feb 4, 2020 05:46AM Sun Pharma Introduces ABSORICA LD™ (Isotretinoin) Capsules for Management of Severe Recalcitrant Nodular Acne in the U.S.
Oct 14, 2019 12:05AM Sun Pharma Launches CEQUA for the Treatment of Dry Eye Disease in the U.S.
Oct 9, 2019 02:20PM Sun Pharma Presents Long-term Study Results that Show Significant Skin Clearance with ILUMYA® (tildrakizumab-asmn) Maintained Over Four Years in People with Moderate-to-Severe Plaque Psoriasis
Jul 17, 2019 07:45AM Sun Pharma Introduces Access Program for Patients Prescribed XELPROS in the U.S.
Jul 15, 2019 12:10AM Sun Pharma Launches Ezallor Sprinkle (Rosuvastatin) in the U.S. for People Who Have Difficulty Swallowing
Jun 14, 2019 02:07AM Sun Pharma Announces Late-Breaking Phase 2 Data Showing Potential of ILUMYA™ (tildrakizumab-asmn) to Improve Joint and Skin Symptoms of Psoriatic Arthritis
Apr 8, 2019 12:05AM Sun Pharma Launches Ready-to-Infuse INFUGEM in the U.S.
Mar 1, 2019 07:31AM ILUMYA™ (tildrakizumab-asmn) 3-Year Data Demonstrates Sustained Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis
Oct 23, 2018 07:02AM Sun Pharma Announces the Availability of ILUMYA™ (tildrakizumab-asmn) in the United States for the Treatment of Moderate-to-Severe Plaque Psoriasis
Sep 14, 2018 12:05AM Sun Pharma and SPARC Announce US FDA Approval of XELPROS™ to Treat Open-angle Glaucoma or Ocular Hypertension
Aug 16, 2018 12:10AM Sun Pharma Announces U.S. FDA Approval of CEQUA™ to Treat Dry Eye Disease
Aug 6, 2018 06:45AM Sun Pharma Launches Novel Drug Kapspargo Sprinkle™ in USA
Jul 11, 2018 08:07AM DUSA Pharmaceuticals, Inc. Files Lawsuit Against Biofrontera Inc. for Patent Infringement, Trade Secret Misappropriation, and Tortious Interference
View More Recent Stories View Older Stories